Physician profile
Lavada Smith
NPI 1164691945
$3,469.36
in general payments reported to CMS, 2019-2025
24 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $123 · 2023: $1,179 · 2024: $1,280 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $333.81 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $315.20 | 2023-2024 | Fasenra, Farxiga |
| Abbott Laboratories | $272.29 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $231.68 | 2022-2023 | Arexvy |
| Corcept Therapeutics | $189.60 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $179.55 | 2024-2025 | Uzedy, Austedo Xr |
| Novo Nordisk INC | $176.09 | 2021-2023 | Wegovy |
| Medtronic, INC. | $137.16 | 2023 | Synchromedii |
| Abbvie INC. | $132.73 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $129.51 | 2023 | Terlivaz |
| Kyowa Kirin, INC. | $121.81 | 2024 | Crysvita |
| Edwards Lifesciences Corporation | $119.11 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Genzyme Corporation | $117.14 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.09 | 2024 | |
| Axsome Therapeutics, INC. | $112.17 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $109.85 | 2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.90 | 2024 | Jardiance |
| Genentech USA, INC. | $106.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $103.26 | 2021 | |
| Exeltis, USA INC. | $101.69 | 2024 | Slynd |
| Tactile Systems Technology INC | $101.44 | 2023 | Flexitouch Plus, Entre Plus |
| Pfizer INC. | $78.89 | 2024 | |
| Idorsia Pharmaceuticals US INC | $46.24 | 2023 | Quviviq |
| Neurelis, INC. | $33.15 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lavada Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.